{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:18:53Z","timestamp":1790068733114,"version":"4.0.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2018,8]]},"abstract":"\n Background and objectives<\/jats:title>\n In the 3-year Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes (TEMPO) 3:4 and 1-year Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trials, tolvaptan slowed the decline of eGFR in patients with autosomal dominant polycystic kidney disease at early and later stages of CKD, respectively. Our objective was to ascertain whether the reduction associated with the administration of tolvaptan is sustained, cumulative, and likely to delay the need for kidney replacement therapy.<\/jats:p>\n <\/jats:sec>\n \n Design, setting, participants, & measurements<\/jats:title>\n \n One hundred and twenty-eight patients with autosomal dominant polycystic kidney disease participated in clinical trials of tolvaptan at the Mayo Clinic. All had the opportunity to enroll into open-label extension studies. Twenty participated in short-term studies or received placebo only. The remaining 108 were analyzed for safety. Ninety seven patients treated with tolvaptan for \u22651 year (mean\u00b1SD, 4.6\u00b12.8; range, 1.1\u201311.2) were analyzed for efficacy using three approaches: (\n 1<\/jats:italic>\n ) comparison of eGFR slopes and outcome (33% reduction from baseline eGFR) to controls matched by sex, age, and baseline eGFR; (\n 2<\/jats:italic>\n ) Stability of eGFR slopes with duration of follow-up; and (\n 3<\/jats:italic>\n ) comparison of observed and predicted eGFRs at last follow-up.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Patients treated with tolvaptan had lower eGFR slopes from baseline (mean\u00b1SD, \u22122.20\u00b12.18 ml\/min per 1.73 m\n 2<\/jats:sup>\n per year) and from month 1 (mean\u00b1SD, \u22121.97\u00b12.44 ml\/min per 1.73 m\n 2<\/jats:sup>\n per year) compared with controls (mean\u00b1SD, \u22123.50\u00b12.09 ml\/min per 1.73 m\n 2<\/jats:sup>\n per year;\n P<\/jats:italic>\n <0.001), and lower risk of a 33% reduction in eGFR (risk ratio, 0.63; 95% confidence interval, 0.38 to 0.98 from baseline; risk ratio, 0.53; 95% confidence interval, 0.31 to 0.85 from month 1). Annualized eGFR slopes of patients treated with tolvaptan did not change during follow-up and differences between observed and predicted eGFRs at last follow-up increased with duration of treatment.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Follow-up for up to 11.2 years (average 4.6 years) showed a sustained reduction in the annual rate of eGFR decline in patients treated with tolvaptan compared with controls and an increasing separation of eGFR values over time between the two groups.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.01520218","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T08:55:42Z","timestamp":1531990542000},"page":"1153-1161","source":"Crossref","is-referenced-by-count":86,"title":["Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.2215","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct00413777","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00428948","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01214421","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01210560","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01451827","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02160145","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02251275","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01039987","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01885559","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01451827","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01210560","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Marie E.","family":"Edwards","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouad T.","family":"Chebib","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria V.","family":"Irazabal","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy G.","family":"Ofstie","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Bungum","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Metzger","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah R.","family":"Senum","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C.","family":"Hogan","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad M.","family":"El-Zoghby","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-9853","authenticated-orcid":false,"given":"Timothy L.","family":"Kline","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Harris","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank S.","family":"Czerwiec","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Development and Commercialization, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,7,19]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","article-title":"Autosomal dominant polycystic kidney disease: The changing face of clinical management.","volume":"385","author":"Ong","year":"2015","journal-title":"Lancet"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2015.59","article-title":"Autosomal-dominant polycystic kidney disease (ADPKD): Executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.","volume":"88","author":"Chapman","year":"2015","journal-title":"Kidney Int"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells.","volume":"66","author":"Belibi","year":"2004","journal-title":"Kidney Int"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","article-title":"Tolvaptan inhibits ERK-dependent cell proliferation, Cl\u2212 secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin.","volume":"301","author":"Reif","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1681\/ASN.2006030251","article-title":"Increased water intake decreases progression of polycystic kidney disease in the PCK rat.","volume":"17","author":"Nagao","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"F261","DOI":"10.1152\/ajprenal.00345.2014","article-title":"Effects of hydration in rats and mice with polycystic kidney disease.","volume":"308","author":"Hopp","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/(SICI)1520-6408(1999)24:3\/4<309::AID-DVG14>3.0.CO;2-5","article-title":"Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease.","volume":"24","author":"Gattone","year":"1999","journal-title":"Dev Genet"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.","volume":"16","author":"Wang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1681\/ASN.2013121312","article-title":"Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.","volume":"26","author":"Hopp","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease.","volume":"19","author":"Wang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1124\/jpet.114.213256","article-title":"Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury.","volume":"349","author":"Aihara","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/jcph.880","article-title":"Pharmacokinetics and pharmacodynamics of tolvaptan in autosomal dominant polycystic kidney disease: Phase 2 trials for dose selection in the pivotal phase 3 trial.","volume":"57","author":"Shoaf","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2215\/CJN.03530411","article-title":"Tolvaptan in autosomal dominant polycystic kidney disease: Three years\u2019 experience.","volume":"6","author":"Higashihara","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ki.2011.119","article-title":"Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.","volume":"80","author":"Irazabal","year":"2011","journal-title":"Kidney Int"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/ki.2013.285","article-title":"Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.","volume":"84","author":"Boertien","year":"2013","journal-title":"Kidney Int"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrneph.2013.22","article-title":"Vasopressin: A novel target for the prevention and retardation of kidney disease?","volume":"9","author":"Bankir","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/ndt\/18.3.497","article-title":"Vasopressin increases urinary albumin excretion in rats and humans: Involvement of V2 receptors and the renin-angiotensin system.","volume":"18","author":"Bardoux","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1046\/j.1523-1755.2001.060002748.x","article-title":"Level of hydration and renal function in healthy humans.","volume":"60","author":"Anastasio","year":"2001","journal-title":"Kidney Int"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease.","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/ndt\/gfx079","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: The TEMPO 4:4 Trial.","volume":"32","author":"Torres","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","article-title":"Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: Analysis of clinical trials database.","volume":"38","author":"Watkins","year":"2015","journal-title":"Drug Saf"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease.","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1056\/NEJMe1714276","article-title":"Tolvaptan and autosomal dominant polycystic kidney disease.","volume":"377","author":"Ingelfinger","year":"2017","journal-title":"N Engl J Med"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease.","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease.","volume":"371","author":"Torres","year":"2014","journal-title":"N Engl J Med"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: A simple model for selecting patients for clinical trials.","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1053\/j.ajkd.2014.11.010","article-title":"Short-term effects of tolvaptan in individuals with autosomal dominant polycystic kidney disease at various levels of kidney function.","volume":"65","author":"Boertien","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1093\/ndt\/13.10.2690","article-title":"Polycystic kidney disease: Antiquity to the 20th century.","volume":"13","author":"Torres","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0272-6386(83)80044-4","article-title":"Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935-1980.","volume":"2","author":"Iglesias","year":"1983","journal-title":"Am J Kidney Dis"},{"key":"B36-20230813","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1523-1755.2003.00776.x","article-title":"Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease.","volume":"63","author":"Schrier","year":"2003","journal-title":"Kidney Int"},{"key":"B37-20230813","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.2215\/CJN.01460210","article-title":"Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark.","volume":"5","author":"Orskov","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B38-20230813","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.ajkd.2011.01.023","article-title":"Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: A population-based study.","volume":"57","author":"Patch","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"B39-20230813","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/ki.2014.120","article-title":"Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease.","volume":"86","author":"Spithoven","year":"2014","journal-title":"Kidney Int"},{"key":"B40-20230813","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.2215\/CJN.00790209","article-title":"A case for water in the treatment of polycystic kidney disease.","volume":"4","author":"Torres","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B41-20230813","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.kint.2016.10.018","article-title":"Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.","volume":"91","author":"Torres","year":"2017","journal-title":"Kidney Int"},{"key":"B42-20230813","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1681\/ASN.2017070819","article-title":"Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney Disease.","volume":"29","author":"Nowak","year":"2018","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201808000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:37:27Z","timestamp":1786369047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201808000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,19]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.01520218","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733673590.793549830","asserted-by":"object"}]},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,19]]}}}